| | |
H3K27me3 expression (%)
| |
|---|
|
Variables
|
Case
|
low
|
high
|
P
|
|---|
|
Age (years)
| | | |
0.255
|
|
≤55a
|
54
|
32(59.3)
|
22(40.7)
| |
|
>55
|
44
|
21(47.7)
|
23(52.3)
| |
|
Gender
| | | |
0.720
|
|
Male
|
82
|
45(54.9)
|
37(45.1)
| |
|
Female
|
16
|
8(50.0)
|
8(50.0)
| |
|
Location
| | | |
0.341
|
|
Cervical
|
24
|
15(62.5)
|
9(37.5)
| |
|
Thoracic
|
74
|
38(51.4)
|
36(48.6)
| |
|
WHO grade
| | | |
0.016
|
|
G1
|
24
|
16(66.7)
|
8(33.3)
| |
|
G2
|
50
|
30(60.0)
|
20(40.0)
| |
|
G3-4
|
24
|
7(29.2)
|
17(70.8)
| |
|
Tumor size (cm)
| | | |
0.019
|
|
≤6b
|
56
|
36(64.3)
|
20(35.7)
| |
|
>6
|
42
|
17(40.5)
|
25(59.5)
| |
|
T status
| | | |
0.024
|
|
T2-3
|
47
|
31(66.0)
|
16(34.0)
| |
|
T4
|
51
|
22(43.1)
|
29(56.9)
| |
|
N status
| | | |
0.929
|
|
N0
|
16
|
8(50.0)
|
8(50.0)
| |
|
N1
|
82
|
40(48.8)
|
42(51.2)
| |
|
M status
| | | |
0.651
|
|
M0
|
59
|
33(55.9)
|
26(44.1)
| |
|
M1-lymc
|
39
|
20(51.3)
|
19(48.7)
| |
|
CRT response
| | | |
0.094
|
|
Effective
|
61
|
37(60.7)
|
24(39.3)
| |
|
Resistant
|
37
|
16(43.2)
|
21(56.8)
| |
|
Locoregional progression
| | | |
0.009
|
|
Absent
|
51
|
34(66.7)
|
17(33.3)
| |
|
Present
|
47
|
19(40.4)
|
28(59.6)
| |
|
Distant progression
| | | |
0.299
|
|
Absent
|
62
|
36(58.1)
|
26(41.9)
| |
|
Present
|
36
|
17(47.2)
|
19(52.8)
| |
-
aMean age. bMean tumor size. cDistant lymph node metastasis.
